Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-531 selpercatinib versus cabozantinib or vandetanib in RET-mutant medullary thyroid cancer
NL-OMON54458Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Medullary Thyroid Cancer (MTC) comparing Selpercatinib, Cabozantinib and Vandetanib (3 arms). Primary endpoint: Progression-free survival by BICR. Started Jun 2021; status: recruiting.
02
Drugs
selpercatinibcabozantinibvandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON54458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54458.